172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Park, S.; Ramaswamy, R.; Roe, C. E.; Irish, J. M.; Caldwell, A.; Wei, W.; Yacoub, A.; more...
    Annals of Hematology (2024)

    Fulltext@MSK | Save
  • Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
    Journal Article

    Strowd, R.; Ellingson, B.; Raymond, C.; Yao, J.; Wen, P. Y.; Ahluwalia, M.; Piotrowski, A.; Desai, A.; Clarke, J. L.; Lieberman, F. S.; more...
    Journal of Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial
    Journal Article

    Bahlis, N. J.; Costello, C. L.; Raje, N. S.; Levy, M. Y.; Dholaria, B.; Solh, M.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial
    Journal Article

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save